- Home
- NG vs MESO Comparison
NG vs MESO Comparison
Compare NG & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NG
- MESO
- Stock Information
- Founded
- NG 1984
- MESO 2004
- Country
- NG Canada
- MESO Australia
- Employees
- NG N/A
- MESO N/A
- Industry
- NG Precious Metals
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NG Basic Materials
- MESO Health Care
- Exchange
- NG Nasdaq
- MESO Nasdaq
- Market Cap
- NG 1.2B
- MESO 1.2B
- IPO Year
- NG N/A
- MESO N/A
- Fundamental
- Price
- NG $3.36
- MESO $13.17
- Analyst Decision
- NG
- MESO Strong Buy
- Analyst Count
- NG 0
- MESO 4
- Target Price
- NG N/A
- MESO $11.50
- AVG Volume (30 Days)
- NG 1.2M
- MESO 238.9K
- Earning Date
- NG 01-22-2025
- MESO 08-28-2024
- Dividend Yield
- NG N/A
- MESO N/A
- EPS Growth
- NG N/A
- MESO N/A
- EPS
- NG N/A
- MESO N/A
- Revenue
- NG N/A
- MESO $5,902,000.00
- Revenue This Year
- NG N/A
- MESO $66.05
- Revenue Next Year
- NG N/A
- MESO $348.27
- P/E Ratio
- NG N/A
- MESO N/A
- Revenue Growth
- NG N/A
- MESO N/A
- 52 Week Low
- NG $2.23
- MESO $1.61
- 52 Week High
- NG $4.88
- MESO $12.70
- Technical
- Relative Strength Index (RSI)
- NG 44.23
- MESO 67.62
- Support Level
- NG $3.35
- MESO $10.30
- Resistance Level
- NG $3.49
- MESO $11.59
- Average True Range (ATR)
- NG 0.17
- MESO 0.50
- MACD
- NG -0.02
- MESO 0.10
- Stochastic Oscillator
- NG 8.18
- MESO 77.98
About NG Novagold Resources Inc.
Novagold Resources Inc is a mineral exploration company engaged in the exploration and development of mineral properties. The company owns 50% of the Donlin Gold project, which is located in southwestern Alaska, approximately 20 kilometers north of the village of Crooked Creek on the Kuskokwim River.
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.